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Abstract: The term fatigue is not only used to describe a sleepy state with a lack of drive, as
observed in patients with chronic physical illnesses, but also a state with an inhibition of drive
and central nervous system (CNS) hyperarousal, as frequently observed in patients with major
depression. An electroencephalogram (EEG)-based algorithm has been developed to objectively
assess CNS arousal and to disentangle these pathophysiologically heterogeneous forms of fatigue.
The aim of this study was to test the hypothesis that fatigued patients with CNS hyperarousal
score higher on depressive symptoms than those without this neurophysiological pattern. Methods:
Subjects with fatigue (Multidimensional Fatigue Inventory sum-score > 40) in the context of cancer,
neuroinflammatory, or autoimmune diseases were drawn from the 60+ cohort of the Leipzig Research
Center for Civilization Diseases. CNS arousal was assessed by automatic EEG-vigilance stage
classification using the Vigilance Algorithm Leipzig (VIGALL 2.1) based on 20 min EEG recordings
at rest with eyes closed. Depression was assessed by the Inventory of Depressive Symptomatology
(IDS-SR). Results: Sixty participants (33 female; median age: 67.5 years) were included in the analysis.
As hypothesized, fatigued patients with CNS hyperarousal had higher IDS-SR scores than those
without hyperarousal (F1,58 = 18.34; p < 0.0001, η2 = 0.240). Conclusion: hyperaroused fatigue in
patients with chronic physical illness may be a sign of comorbid depression.
Keywords: depression; fatigue; electroencephalography; hyperarousal; neurophysiology
1. Introduction
Fatigue is a widespread symptom among patients with cancer, neuroinflammatory or autoimmune
disease. For example, severe chronic fatigue is reported in 41–57% of patients with rheumatoid
arthritis [1], and in 67% of patients with Sjogren’s syndrome [2]. Among cancer patients, the prevalence
rate ranges from 59% to 100%, depending on the clinical status of the cancer [3]. In patients with
Parkinson’s disease, prevalence rates between 37% and 57% [4] have been reported. Moreover,
more than 80% of multiple sclerosis patients suffer from intractable chronic fatigue within the first year
of disease onset [5].
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However, fatigue is also a symptom and prodromal symptom in major depression (MD; [6]), which
is a frequent comorbid diagnosis in patients with the somatic disorders mentioned above, with estimated
prevalence rates of between 17% and 40% [7–10]. Evidence has been provided that fatigue in the context
of inflammatory and immunological processes should not be confused with fatigue in MD, because
they show profound neurophysiological differences—especially concerning central nervous system
(CNS) arousal [11,12]. A differentiation of these distinct forms of fatigue along the dimension of CNS
arousal may have implications for treatment [11–13]. Transdiagnostically, the dimension of arousal
gained relevance within a new research framework for studying mental illnesses—the Research Domain
Criteria (RDoC) Project [14]—wherein arousal and its regulation constitute one of the five fundamental
dimensions. The term brain arousal refers to global brain states which, on a behavioral level, vary along a
continuum between wakefulness and sleep. It can be assessed using a resting state electroencephalogram
(EEG; [15,16]) by automatic EEG-vigilance stage classification with the Vigilance Algorithm Leipzig
(VIGALL; [17]; for the validation of VIGALL, see [18–22]). Resting state eyes-closed EEG has been
extensively used to study CNS arousal, providing data largely free of eye-movement artifacts and not
confounded by a subject’s ability (and motivation) to maintain wakefulness, as required by eyes-open or
eyes fixating on a cross paradigms. The classification with VIGALL takes into account frequency patterns
and the cortical distribution of EEG activity by utilizing low resolution electromagnetic tomography
(LORETA; [23]). Using this tool, inter-individual differences in the regulation of brain arousal during a
20 min resting state EEG can be discerned. While most individuals show progressive declines to lower
EEG-vigilance stages (i.e., drowsy or sleepy) during the resting state EEG, others remain in a state of high
arousal (i.e., alert or hypervigilant) throughout the recording. Such hyperarousal is a frequent finding
in medicated and unmedicated patients with MD [24–27], and it has been shown to correlate with
symptom severity in MD patients [27]. In addition, at the gene level, a genome-wide association study
(GWAS) revealed significant evidence of an association of brain arousal with TMEM159, with other
GWAS analyses and gene expression data suggesting a role of TMEM159 in MD [28]. Other indicators
of hyperarousal in MD, such as prolonged sleep onset latencies [29,30], increased heart rate and skin
conductance levels [31], or hyperactivity of the hypothalamic-pituitary-adrenal (HPA)-axis [32], are in
line with the view that arousal may play a significant pathophysiological role in MD.
In contrast to the hyperarousal frequently observed in depression, evidence has been provided
that fatigue in the context of somatic disorders may be associated with hypoarousal. This is supported
by previous findings of a fast decline to low arousal levels during a 15 min EEG at rest in fatigued cancer
patients [33]. It is also corroborated by the inflammatory response model of fatigue [34], suggesting an
upregulation of proinflammatory and sleep-promoting cytokines (i.e., Interleukin-1 beta (IL-1) and
tumor necrosis factor-α (TNF-α)) in fatigued patients with physical illness. Indeed, the association of
IL-1 and TNF-α with fatigue has been demonstrated in several medical conditions [35,36]. Additionally,
associations between TNF-α and sleepiness have been reported [25,37].
In view of these findings, we have proposed to define two subtypes of fatigue based on their
assumed underlying neurobiological mechanisms concerning arousal regulation [11,12]—hyperaroused
fatigue with reduced sleep propensity, inhibition of drive and exhaustion (typical of depression),
and hypoaroused fatigue with increased sleepiness, a lack of drive, and sickness behaviour, typical in
context of inflammatory and immunological processes [11].
Up to now, there has been little research on the association between depressive symptoms and
CNS arousal in patients with fatigue and physical illness. The question is justified because of the high
prevalence rates of comorbid depression. There is first evidence that hyperaroused fatigue in these
conditions may be accompanied by CNS hyperarousal. For example, although fatigue in multiple
sclerosis has been reported to co-occur with excessive daytime sleepiness [38,39] and short sleep onset
latencies in the multiple sleep latency test (MSLT; [39]), HPA-axis upregulation in multiple sclerosis
patients with fatigue was also reported [40]. Furthermore, increased HPA-axis activity was found to
be associated with hyperstable arousal regulation in medicated patients with multiple sclerosis [41].
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Therefore, based on the accumulated evidence outlined above, we expect that CNS hyperarousal
would be indicative of depression.
The aim of this study was to test the hypothesis that fatigued patients with CNS hyperarousal have
a higher depression score than those without this neurophysiological pattern. Participants with cancer
or neuroinflammatory or autoimmune disease—complaining about fatigue—were selected from a
population-based study, the Leipzig Research Center for Civilization Diseases (LIFE)-Adult-Study [42].
All had undergone a comprehensive medical assessment, including a 20 min eyes-closed resting
EEG. The Vigilance Algorithm Leipzig (VIGALL 2.1, licensed under GPL3) was used to score the
EEG-vigilance stages (indicating arousal states) for each 1 s epoch of the resting EEG. The individual
arousal regulation type was determined based on the time course of the arousal stages. Individuals
with and without CNS hyperarousal were compared regarding their depression score and, within
sensitivity analyses, concerning their depressive symptom profiles.
2. Materials and Methods
2.1. Sample
The participants were drawn from the 60+ LIFE cohort of the LIFE-Adult-Study, a population-based
cohort study in Leipzig, Germany [42]. All participants had given written informed consent, and all
the procedures were conducted according to the Declaration of Helsinki and were approved by the
Ethics Committee of the University of Leipzig (263-2009-14122009). We selected study participants
(age range: 60–70) with cancer or neuroinflammatory or autoimmune disease (to be present within the
last 12 months and/or treated at time of assessment), with a sum-score of >40 in the Multidimensional
Fatigue Inventory (MFI-20; [43]), who had undergone a 20 min resting-state EEG (n = 72). We excluded
participants with substance dependence; participants with psychotic, affective, or anxiety disorders
(assessed with the Structured Clinical Interview for DSM-IV axis I disorders; [44]); and participants on
antidepressant medication, benzodiazepines, and z-hypnotics. We also excluded participants with
pathological EEG activity, low-voltage alpha or alpha-variant rhythms, or with substantial artifacts in
the EEG. The final sample consisted of 60 participants (33 female; median age: 67.5).
2.2. Questionnaires
Fatigue was assessed with the MFI-20, a 20-item self-rating questionnaire consisting of five
fatigue dimensions: general fatigue, physical fatigue, mental fatigue, reduced activity, and reduced
motivation [43]. Each dimension contains four items ranging from 1 to 5, with higher scores indicating
a higher degree of fatigue. A sum-score over 40 was used as cut-off-point, analogous to the study by
Olbrich et al. [33], in which the presence of fatigue in cancer patients with a MFI cut-off-point above 40
was validated by a senior physician.
The sum-score of the self-rating version of the Inventory of Depressive Symptomatology
(IDS-SR; [45]), a 30-item questionnaire, was used to assess the severity of depression (no depressive
symptomatology: IDS-SR < 14; mild depressive symptom severity: 14 ≤ IDS-SR < 26; moderate
depressive symptom severity: 26 ≤ IDS-SR < 39; severe depressive symptom severity: IDS-SR ≥ 39).
Sleep quality and sleep duration were assessed using the German version of the Pittsburgh
Sleep Quality Index (PSQI; [46]), which assesses subjectively rated sleep. The PSQI is a 19-item
questionnaire designed to measure sleep quality and disturbance over the past month in clinical
populations. The sleep component scores are summed to yield a total score ranging from 0 to 21, with
a higher total score indicating worse sleep quality [46]. Trait daytime sleepiness was assessed with
the Epworth Sleepiness Scale (ESS; [47]), an 8-item questionnaire, with scores over 10 indicating mild
excessive daytime sleepiness [48].
2.3. EEG Recording and Preprocessing
EEGs were recorded and processed according to a standard operating procedure [17]. During the
recording, the participants lay on a semi-reclined lounge chair in a sound- and light attenuated
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booth. Before the recording, the participants were asked to complete a simple arithmetic task
(counting backwards by sixes starting at 100) to ensure similar arousal levels between subjects.
Thereafter, they were instructed to close their eyes and to relax during the 20 min resting condition.
Electroencephalographic and electro-oculographic activities were recorded with a sampling rate of
1000 Hz from 31 electrode sites, following an extended 10–20 system using a QuickAmp-40 amplifier
(Brain Products GmbH, Gilching, Germany). Impedances were kept below 10 kΩ. EEG offline
processing was conducted in BrainVision Analyser 2.1 (Brain Products GmbH, Gilching, Germany).
After filtering (0.5 Hz high-pass, 70 Hz low-pass, with a 48 dB/Oct slope and 50 Hz notch filter),
the data were segmented into 1 s epochs and down-sampled to 500 Hz for further preprocessing
(and again to 100 Hz immediately before VIGALL application). Graphoelements indicating sleep onset
(sleep spindles, K-complexes) were marked by experienced raters according to set criteria, as these
markers are used by VIGALL to classify C-stages. Using independent component analysis (ICA; [49]),
components corresponding to muscle, sweating, cardiac, and eye movement artifacts were removed
(in most cases, 2 eye and 1 cardiac component and up to 5 components containing muscle or other
artifacts, depending on which components were found). Afterwards, segments with remaining artifacts
(approximately 2% of all segments) were marked (and not classified by VIGALL).
2.4. EEG-Vigilance Staging and Parameterization
To assess CNS arousal, we applied VIGALL 2.1 to the 20 min EEG to classify each of the 1200
1 s segments into one-out-of-seven EEG-vigilance stages, ranging from active wakefulness (Stage 0) to
sleep onset (Stage C), including Stage 0 (low-voltage EEG without slow horizontal eye movements),
Stage A (dominant alpha rhythm; cortical areas: A1 (occipital); A2 (central); A3 (frontal)), Stage B1
(low-amplitude non-alpha EEG with slow horizontal eye movements), Stage B2/3 (high delta and theta
power), and Stage C (occurrence of sleep spindles, K-complexes, sleep onset). Subsequently, using the
scoring criteria presented in Table 1, we calculated an Arousal Stability Score [30] for each participant,
to assess the degree of arousal decline during the 20 min resting EEG. We divided the patients into
two groups: patients with hyperaroused fatigue (Arousal Stability Score ≥ 13) and patients with
non-hyperaroused fatigue (Arousal Stability Score ≤ 12). The rationale for this cut-off was based on
previous findings in depressed patients [24,25], who remained in high EEG-vigilance stages during an
EEG at quiet rest (indicating hyperarousal). An Arousal Stability Score of 13 or 14 indicates that more
than 2/3 of all the segments in each of the twenty 1 min epochs were classified as at least Stage A or
higher (Table 1).
Table 1. Scoring criteria of the Arousal Stability Score. The score quantifies the degree of arousal
decline on the basis of subsequently classified 1 s EEG segments with VIGALL 2.1.
Score Scoring Criteria EEG Block Operational Definition
14 More than 2/3 of all segments in each 1 min
epoch classified as 0/A1- or 0/A-stages
1–4 Predominant classification of 0 and A1
13 1–4 Predominant classification of 0 and A
12 At least 1/3 of all segments in a 1 min epoch
classified as B1-stages
4 Stage B1 emerged in min 16–20
11 3 Stage B1 emerged in min 11–15
10 2 Stage B1 emerged in min 6–10
9 1 Stage B1 emerged in min 1–5
8 At least 1/3 of segments in a 1 min epoch 4 Stage B2/3 emerged in min 16–20
7 classified as B2/3-stages 3 Stage B2/3 emerged in min 11–15
6 2 Stage B2/3 emerged in min 6–10
5 1 Stage B2/3 emerged in min 1–5
4 At least one C-stage classified 4 Stage C emerged in min 16–20
3 3 Stage C emerged in min 11–15
2 2 Stage C emerged in min 6–10
1 1 Stage C emerged in min 1–5
Annotations: EEG block 1 = min 1–5, EEG block 2 = min 6–10, EEG block 3 = min 11–15, EEG block 4 = min 16–20.
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2.5. Statistical Analyses
Statistical analyses were conducted in SPSS Statistics 24 (IBM corp., Armonk, NY, USA). To identify
the relevant covariates for the between-group comparison of the depression score, we analyzed the
differences in demographic and clinical variables between the arousal groups using parametric (t-test) or
nonparametric tests (Chi2, Mann–Whitney U) depending on data level and their distribution. The term
gender was defined as male or female sex. For the main analysis, an analysis of variance (ANOVA) was
utilized to calculate the between-group differences in the IDS-SR sum-score. The significance level was
set at p = 0.05 (one-tailed). For the exploratory sensitivity analyses, we employed two-tailed tests.
3. Results
3.1. Descriptive Analyses
The characteristics of the total sample and of the arousal subgroups are described in Table 2.
Of the 60 study participants, 31.7% (n = 19) had an Arousal Stability Score of 13 or higher, indicating
that they remained in high arousal states during the 20 min EEG. Those 19 participants were assigned
to the hyperaroused fatigue subgroup; all the others (n = 41) were assigned to the non-hyperaroused
fatigue subgroup (cf. Table 2). Forty percent of the participants (n = 24) did not report any depressive
symptoms, 53.3% (n = 32) had mild ones, and 6.7% (n = 4) had moderate to severe depressive symptom
severity. The hyperaroused subgroup did not differ from the non-hyperaroused subgroup in regard
to age, type of physical illness, daytime sleepiness, and severity of fatigue (p < 0.390). There was a
statistical trend for significant differences concerning gender (χ2 = 3.92; df = 1; p = 0.057), wherein
female participants tended to have higher arousal levels than male participants. There were no
group differences concerning the time of day of the EEG recording, coffee consumption prior the
EEG recording, and daytime sleepiness (cf. Table 3). The self-rated sleep quality, as assessed by the
PSQI total score, differed between groups (Z = −2.78; p = 0.005), indicating worse sleep quality in the
hyperaroused as compared to the non-hyperaroused subgroup. However, the frequency distribution
of PSQI phenotypes (cf. Table 3) did not differ between the groups (χ2 = 3.680; p = 0.159).
Table 2. Characteristics of the total sample, and the arousal subgroups.
All (n = 60) Hyperaroused(n = 19)
Non-Hyperaroused
(n = 41)
Demographics
Age, median years 67.5 68.0 67.0
Sex, f/m (%) 33/27 (55.0/45.0) 14/5 (73.7/26.3) 19/22 (46.3/53.7)
Cancer, n (%) 30 (50.0) 10 (52.6) 20 (48.8)
Skin cancer 10 4 6
Breast cancer 9 3 6
Prostata cancer 4 0 4
Bladder cancer 2 1 1
Colon cancer 2 1 1
Kidney cancer 1 0 1
Lymphoma 1 1 0
Thyroid cancer 1 0 1
Neuroinflammatory/autoimmune, n (%) 30 (50.0) 9 (47.4) 21 (51.2)
Rheumatoid arthritis 19 7 12
SLE/Sjogren syndrome 10 1 9
Multiple sclerosis 2 1 1
Parkinson’s disease 2 1 1
Fatigue
MFI, median sum-score 52.0 55.0 51.0
Annotations: MFI = Multiple Fatigue Inventory; SLE = Systemic Lupus Erythematosus.
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Table 3. Description of arousal-related variables in the total sample, and in the arousal subgroups.
All (n = 60) Hyperaroused(n = 19)
Non-Hyperaroused
(n = 41)
Arousal Stability Score, median 10.0 13.0 9.0
ESS, mean score (SD) 7.9 ± 3.4 6.8 ± 3.0 8.3 ± 3.6
PSQI, mean score (SD) 6.5 ± 3.5 8.4 ± 3.6 5.6 ± 3.1
Good sleep quality, n (%) 26 (47.3) 5 (29.4) 21 (55.3)
Poor sleep quality, n (%) 19 (34.6) 7 (41.2) 12 (31.6)
Potentially clinically relevant sleep disorder, n (%) 10 (18.2) 5 (29.4) 5 (13.2)
Total time in bed, median hours (range) 8.6 (4.0–12.5) 9.0 (6.5–12.5) 8.5 (4.0–10.0)
EEG-Related Variables
Time of EEG recording, median, hh:mm 9:00 9:00 9:00
Coffee prior to EEG, yes (%) 51 (85.0) 16 (84.2) 35 (85.4)
Annotations: ESS = Epworth Sleepiness Scale; PSQI = Pittsburgh Sleep Quality Index (only n = 55 (hyperaroused:
n = 17; non-hyperaroused: n = 38) with available data).
3.2. Main Analysis: Between-Group Comparisons of the Depression Score
The hyperaroused subgroup (IDS-SR sum-score: 20.6 ± 7.3, range 10–41) scored higher on
depression than the non-hyperaroused subgroup (IDS-SR sum-score: 12.6 ± 6.2, range 1–24).
We conducted a one-way ANOVA to assess the level of depressive symptomatology across the
subgroups (hyperaroused vs non-hyperaroused). Levene’s test of significance indicated that the
assumption of homogeneity of variance was met (F(1, 58) = 0.559; p = 0.458). The main group effect was
significant (F(1, 58) = 18.340; p < 0.0001; η2p = 0.240), indicating that patients with hyperaroused fatigue
scored significantly higher on the IDS-SR than patients with non-hyperaroused fatigue (cf. Figure 1A).
To control for gender, a two-way ANOVA was conducted with gender as additional factor (respective
means in either group are presented in Figure 1B). Levene’s test for the equality of variances was
met (F(3, 56) = 0.089; p = 0.966). The main group effect was still significant (F(1, 56) = 11.80; p = 0.001;
η2p = 0.174) when gender was included as a factor in the model, whereas the effect of gender was not
significant (F(1, 56) = 2.150; p = 0.152; η2p = 0.036), indicating that gender had no significant effect on
the level of depressive symptomatology. Furthermore, there was no significant interaction between
group and gender (F(1, 56) = 0.181; p = 0.672; η2p = 0.003).
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Figure 1. Between-group comparisons (hyperaroused (n = 19) vs. non-hyperaroused (n = 41)).
(A) Between-group comparison of the mean sum-score of the Inventory of Depressive Symptomatology
(IDS-SR). (B) Between-group comparison of the IDS-SR means, stratified by gender.
Post-hoc receiver operating characteristic (ROC) analyses, examining arousal stability (at the
cut-off score of 13) as a diagnostic screening test for moderate to severe depression, revealed a 0.87 area
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under the curve (AUC; p = 0.014; 95% CI 0.765–0.976), indicating a sensitivity of 100%, a specificity of
73%, and a Youden Index of 0.7 [50].
3.3. Exploratory Sensitivity Analyses: Between-Group Comparisons of IDS-SR Items
To assess whether the arousal groups differ concerning typical depressive symptoms, we conducted
Mann–Whitney U (MWU) tests. MWU tests revealed significant differences between the hyperaroused
and the non-hyperaroused subgroups in items initial insomnia (Z = −3.803, p < 0.001), early morning
awakening (Z = −3.368, p < 0.0001), feeling sad (Z = −2.517, p = 0.012), feeling anxious or tense
(Z = −2.874, p = 0.004), increased appetite (Z = −2.202, p = 0.028), concentration/decision-making
(Z = −3.070; p = 0.002), self-criticism/blame (Z = −2.361, p = 0.018), energy level (Z = −2.940, p = 0.003),
psychomotor retardation (Z = −3.033, p = 0.002), and agitation (Z = −3.046, p = 0.002). Relative to
individuals in the non-hyperaroused group, individuals in the hyperaroused group took a longer time
to fall asleep and woke up too early; felt more often sad, anxious, or tense; felt more often slowed down
or restless; had more frequently a negative view of themselves; experienced more often concentration
and decision-making problems; had an increased appetite and a lower energy level.
4. Discussion
The aim of the current study was to test the hypothesis that fatigued patients with chronic physical
illnesses, and CNS hyperarousal during a 20 min EEG at rest, have a higher depression score than
those without this neurophysiological pattern. The hypothesis was confirmed; individuals with
hyperaroused fatigue had significantly higher depression scores than those with non-hyperaroused
fatigue; an eta-squared value of over 0.2 indicated a large effect size. The between-group differences in
depression scores remained significant when gender was included as a factor in the model. In sensitivity
analyses, individuals in the hyperaroused group achieved higher scores in a series of depressive
symptoms, such as depressed mood, insomnia, and concentration/decision-making problems, as
compared to individuals in the non-hyperaroused group.
Our results are in line with a previous study examining arousal regulation in multiple sclerosis
patients with fatigue, wherein evidence for distinct pathophysiological correlates of fatigue was
provided [41]. In this study, the hyperaroused fatigue subtype, as assessed by EEG-vigilance using
VIGALL, corresponded to the highest HPA-axis activity, while the hypoaroused fatigue subtype
revealed the lowest HPA-axis activity [41]. These findings, as the results of the current study,
corroborate the validity of the distinction of fatigue subtypes along the axis of brain arousal and of
CNS hyperarousal as a state marker of depression [11,12,24].
Group differences in the IDS-SR total score between patients with and without hyperarousal, as
revealed by exploratory item comparisons, emerged not merely due to confounding symptoms of the
underlying disease, such as pain, weight changes, or negative view of the future. Instead, individuals
in the hyperaroused group achieved higher scores in a series of typical symptoms of depression,
including depressed mood, concentration/decision-making difficulties, and sleep and psychomotor
changes. An inconsistency was the reported increased appetite in the hyperaroused group, which is
more often associated with the atypical depressive subtype [51]. A possible explanation consists in
the fact that our sample was composed of individuals with chronic physical illnesses, which may be
accompanied by changes in appetite by themselves. Although subjects with current major depression,
as assessed by a structured clinical interview, were excluded, 7% of the sample complained about
moderate to severe depressive symptoms, possibly revealing discrepancies between the self-rating
and physician-rating scales. Further, 53% of the sample reported mild depressive symptoms. To date,
an association between hyperarousal and depressive symptoms has been frequently demonstrated in
the context of major depression [24–26]; our results suggest that this association could exist within
subthreshold depressive symptomatology.
The sleep quality, assessed with the PSQI, differed significantly between the arousal
groups—hyperaroused individuals reported worse sleep quality. In contrast, daytime sleepiness,
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assessed with ESS, was comparable. In healthy individuals, one would expect that poor sleep at night
would be associated with increased daytime sleepiness and CNS hypoarousal. In patients with major
depression, however, CNS hyperarousal is considered an important pathogenetic mechanism leading
to both sleep problems and increased brain arousal during the day [30,52]. This could explain the
co-occurrence of poor sleep quality and high daytime arousal in the current study.
Three limitations should be mentioned: (i) the presence of chronic physical diseases was assessed
via self-reporting without validation by a medical specialist; (ii) the applied questionnaires (physical
disease diagnoses) were designed specifically for the LIFE study and have not been externally validated;
(iii) the advanced age of the sample (median age: 67.5 years) limits the generalizability of the study.
Despite these limitations, the hypothesis that a subgroup of hyperaroused fatigued patients with
somatic disorders might suffer from undetected depression, has been confirmed. Considering the
relevancy for treatment decisions, future clinical trials stratifying fatigued patient by patterns of brain
arousal for treatment allocation, are warranted.
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